Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 27;10(2):201.
doi: 10.3390/vaccines10020201.

Is the BCG Vaccine an Answer to Future Pandemic Preparedness?

Nadia H Khan  1 , Nadine G Rouphael  2 , Lindsey R Baden  3 , Daniel S Graciaa  2
Affiliations

Is the BCG Vaccine an Answer to Future Pandemic Preparedness?

Nadia H Khan et al. Vaccines (Basel). .

Abstract

While the development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines was rapid, time to development and implementation challenges remain that may impact the response to future pandemics. Trained immunity via bacille Calmette-Guerin (BCG) vaccination (an antigen agnostic strategy) offers a potential intervention against future novel pathogens via an existing, safe, and widely distributed vaccine to protect vulnerable populations and preserve health system capacity while targeted vaccines are developed and implemented.

Keywords: BCG; COVID-19; pandemic preparedness.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Immunologic & Implementation Rationale for BCG Vaccination for Pandemic Preparedness.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. World Health Organization. [(accessed on 19 January 2022)]. Available online: https://covid19.who.int/
    1. Bregu M., Draper S.J., Hill A.V.S., Greenwood B.M. Accelerating vaccine development and deployment: Report of a Royal Society satellite meeting. Philos. Trans. R. Soc. B Biol. Sci. 2011;366:2841–2849. doi: 10.1098/rstb.2011.0100. - DOI - PMC - PubMed
    1. Madhi S.A., Baillie V., Cutland C.L., Voysey M., Koen A.L., Fairlie L., Padayachee S.D., Dheda K., Barnabas S.L., Bhorat Q.E., et al. Efficacy of the ChAdOx1 nCoV-19 COVID-19 Vaccine against the B.1.351 Variant. N. Engl. J. Med. 2021;384:1885–1898. doi: 10.1056/NEJMoa2102214. - DOI - PMC - PubMed
    1. Edara V.V., Norwood C., Floyd K., Lai L., Davis-Gardner M.E., Hudson W.H., Mantus G., Nyhoff L.E., Adelman M.W., Fineman R., et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe. 2021;29:516–521.e2. doi: 10.1016/j.chom.2021.03.009. - DOI - PMC - PubMed
    1. Liu Y., Liu J., Xia H., Zhang X., Fontes-Garfias C.R., Swanson K.A., Cai H., Sarkar R., Chen W., Cutler M., et al. Neutralizing Activity of BNT162b2-Elicited Serum. N. Engl. J. Med. 2021;384:1466–1468. doi: 10.1056/NEJMc2102017. - DOI - PMC - PubMed

LinkOut - more resources